Skip to main content

Table 4 Outcomes in rhTPO group

From: Recombinant human thrombopoietin therapy for primary immune thrombocytopenia in pregnancy: a retrospective comparative cohort study

Variables

No response

(n = 16)

Response

(n = 17)

Statistical value

P

Platelets before delivery (× 109/L)

19 (17.3, 25)

68 (48.5, 112)

-4.909a

 < 0.001

Platelet transfusion, n (%)

  

NA

 < 0.001b

 No

0 (0)

14 (82.4)

  

 Yes

16 (100)

3 (17.6)

  

Gestational weeks of delivery (weeks)

37 (36, 37.4)

38.3 (38, 39.3)

-4.151a

 < 0.001

Mode of delivery

  

NA

 < 0.001b

 Vaginal delivery, n (%)

0 (0)

11 (64.7)

  

 Cesarean section, n (%)

16 (100)

6 (35.3)

  

Postpartum hemorrhage, n (%)

  

NA

0.085b

 No

11 (68.8)

16 (94.1)

  

 Yes

5 (31.30)

1 (5.9)

  

Postpartum hemorrhage (ml)

600 (350, 1000)

400 (159, 550)

-1.835a

0.066

Premature, n (%)

  

NA

0.085b

 No

11 (68.8)

16 (94.1)

  

 Yes

5 (31.3)

1 (5.9)

  
  1. Platelets before delivery: platelet counts before platelet transfusion before delivery
  2. Postpartum hemorrhage was defined as a blood loss of ≥ 500 ml from the genital tract for vaginal deliveries and ≥ 1000 ml for caesarean sections, within 24 h of delivery
  3. Abbreviations: NA not applicable
  4. aMann-Whitney U Test
  5. bFisher exact probability test